Identification of a Novel Isoform of iASPP and its Interaction with p53

Journal of Molecular Biology

Volumn 368, Issue 4, 2007, Pages 1162-1171

  Zhang, Xinwei ^a   Diao, Shiyong ^a   Rao, Qing ^a   Xing, Haiyan ^a   Liu, Hang ^a   Liao, Xiaolong ^a   Wang, Min ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

ASPP; iASPP; p53; transcription

Indexed keywords

ANKYRIN; NUCLEAR PROTEIN; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PROTEIN SH3;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN VARIANT; RNA PURIFICATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

EID: 34247143604     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.03.001     Document Type: Article

References (56)

1. Hofseth L.J., Hussain S.P., and Harris C.C. p53: 25 years after its discovery. Trends Pharmacol. Sci. 25 (2004) 177-181
2. Fields S., and Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science 249 (1990) 1046-1049
3. Muller-Tiemann B.F., Halazonetis T.D., and Elting J.J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl Acad. Sci. USA 95 (1998) 6079-6084
4. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
5. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., and Sakaguchi K. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol. 2 (1995) 321-333
6. Ahn J., and Prives C. The C-terminus of p53: the more you learn the less you know. Nature Struct. Biol. 8 (2001) 730-732
7. Zhu J., Zhang S., Jiang J., and Chen X. Definition of the p53 functional domains necessary for inducing apoptosis. J. Biol. Chem. 275 (2000) 39927-39934
8. Walker K.K., and Levine A.J. Identification of the novel p53 functional domain which is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA 93 (1996) 15335-15340
9. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K. W., and Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1 (1992) 45-49
10. Funk W.D., Pak D.T., Karas R.H., Wright W.E., and Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12 (1992) 2866-2871
11. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124 (2006) 207-219
12. Oren M. Decision making by p53: life, death and cancer. Cell Death Diff. 10 (2003) 431-442
13. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucl. Acids Res. 26 (1998) 205-213
14. Gorina S., and Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274 (1996) 1001-1005
15. Iwabuchi K., Bartel P.L., Li B., Marraccino R., and Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl Acad. Sci. USA 91 (1994) 6098-6102
16. Naumovski L., and Cleary M.L. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol. Cell. Biol. 16 (1996) 3884-3892
17. Iwabuchi K., Li B., Massa H.F., Trask B.J., Date T., and Fields S. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem. 273 (1998) 26061-26068
18. Trigiante G., and Lu X. ASPPs and cancer. Nature Rev. Cancer 6 (2006) 217-226
19. Slee EA., and Lu X. The ASPP family: deciding between life and death after DNA damage. Toxicol. Letters 139 (2003) 81-87
20. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8 (2001) 781-794
21. Bergamaschi D., Samuels Y., Jin B., Duraisingham S., Crook T., and Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell. Biol. 24 (2004) 1341-1350
22. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., Hsieh J.K., et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nature Genet. 33 (2003) 162-167
23. Slee E.A., Gillotin S., Bergamaschi D., Royer C., Llanos S., Ali S., et al. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 23 (2004) 9007-9016
24. Yang J.P., Hori M., Sanda T., and Okamoto T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J. Biol. Chem. 274 (1999) 15662-15670
25. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nature Genet. 38 (2006) 1133-1141
26. Lohrum M., and Scheidtmann K.H. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 13 (1996) 2527-2539
27. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
28. Bulavin D.V., Demidov O.N., Saito S., Kauraniemi P., Phillips C., Amundson S.A., et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet. 31 (2002) 210-215
29. Chehab N.H., Malikzay A., Appel M., and Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14 (2000) 278-288
30. Jack M.T., Woo R.A., Hirao A., Cheung A., Mak T. W., and Lee P.W. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl Acad. Sci. USA 99 (2002) 9825-9829
31. Shikama N., Lee C.W., France S., Delavaine L., Lyon J., Krstic-Demonacos M., et al. A novel cofactor for p300 that regulates the p53 response. Mol. Cell 4 (1999) 365-376
32. Frade R., Balbo M., and Barel M. RB18A, whose gene is localized on chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity. Cancer Res. 60 (2000) 6585-6589
33. Rozenfeld-Granot G., Krishnamurthy J., Kannan K., Toren A., Amariglio N., Givol D., et al. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene 21 (2002) 1469-1476
34. Tidow H., Veprintsev D.B., Freund S.M., and Fersht A. R. Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53 binding protein 2 (53BP2). J. Biol. Chem. 281 (2006) 32526-32533
35. Yu H., Chen J.K., Feng S., Dalgarno D.C., Brauer A. W., and Schreiber S.L. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76 (1994) 933-945
36. Berger M., Vogt Sionov R., Levine A.J., and Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J. Biol. Chem. 276 (2001) 3785-3790
37. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
38. Edwards S.J., Hananeia L., Eccles M.R., Zhang Y.F., and Braithwaite A.W. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 22 (2003) 4517-4523
39. Baptiste N., Friedlander P., Chen X., and Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21 (2002) 9-21
40. Zhu J., Jiang J., Zhou W., Zhu K., and Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18 (1999) 2149-2155
41. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., and Wahl G.M. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9 (2006) 273-285
42. D'Erchia A.M., Pesole G., Tullo A., Saccone C., and Sbisa E. Guinea pig p53 mRNA:identification of new elements in coding and untranslated regions and their functional and evolutionary implications. Genomics 58 (1999) 50-64
43. Dumont P., Leu J.I., Della A., Pietra III C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet. 33 (2003) 357-365
44. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 108 (2004) 196-199
45. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
46. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19 (1999) 1092-1100
47. Salvioli S., Bonafe M., Barbi C., Storci G., Trapassi C., Tocco F., et al. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4 (2005) 1264-1271
48. Zhang X., Wang M., Zhou C., Chen S., and Wang J. The expression of iASPP in acute leukemias. Leuk. Res. 29 (2005) 179-183
49. Mori T., Okamoto H., Takahashi N., Ueda R., and Okamoto T. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Letters 465 (2000) 124-128
50. Mori S., Ito G., Usami N., Yoshioka H., Ueda Y., Kodama Y., et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 100 (2004) 1673-1682
51. Agirre X., Roman-Gomez J., Jimenez-Velasco A., Garate L., Montiel-Duarte C., Navarro G., et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25 (2006) 1862-1870
52. Sgroi D.C., Teng S., Robinson G., LeVangie R., Hudson Jr. J.R., and Elkahloun A.G. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 59 (1999) 5656-5661
53. Liu Z.J., Lu X., Zhang Y., Zhong S., Gu S.Z., Zhang X.B., et al. Downregulated mRNA expression of ASPP and the hypermethylation of the 50-untranslated region in cancer cell lines retaining wild-type p53. FEBS Letters 579 (2005) 1587-1590
54. Dabrowski S., Kiaer, and Ahring B. Cloning, expression, and purification of the His6-tagged hyper-thermostable dUTPase from Pyrococcus woesei in Escherichia coli: application in PCR. Protein Expr. Purif. 31 (2003) 72-78
55. Velikovsky C.A., Cassataro J., Sanchez M., Fossati C.A., Fainboim L., and Spitz M. Single-shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies persistent expression of DNA. J. Immunol. Methods 244 (2000) 1-7
56. Moonsom S., Khunkeawla P., and Kasinrerk W. Production of polyclonal and monoclonal antibodies against CD54 molecules by intrasplenic immunization of plasmid DNA encoding CD54 protein. Immunol. Letters 76 (2001) 25-30